Royalty Report: Drugs, cell therapy, Therapeutic – Collection: 249983

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 7

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 7

Primary Industries

  • Drugs
  • cell therapy
  • Therapeutic
  • Medical
  • Regenerative medicine
  • Diabetes Treatment
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 249983

License Grant
With the Joint Venture, the Licensor and the Japanese Licensee will collaborate in the clinical development and commercialization of the Products in Japan.  

In addition, under the JVA, the Licensor shall grant the JV Company an exclusive license to certain intellectual property of the Company as may be required for the JV Company to develop and commercialize the Products in Japan.

License Property
The licensed property is the intellectual property needed for the development and commercialization of the products.  The products are regeneration and cell and gene therapeutic products.
Field of Use
The Licensor is a service and research company in the field of the regenerative medicine industry with a focus on cell therapy development and manufacturing for advanced medicinal products. In addition, the Company is focused on developing novel and proprietary cell therapy trans-differentiation technologies for the treatment of diabetes.

IPSCIO Record ID: 270501

License Grant
With the Joint Venture Agreement (JVA), the parties will collaborate in the clinical development and commercialization of the products.

In addition, under the JVA, the Company shall, subject to fulfilment of the obligations to the JV, grant the JV an exclusive license to certain intellectual property of the Company as may be required for the JV to develop and commercialize the Products in the Territory, subject to minimum sales obligations.

License Property
The licensed property is the intellectual property needed for the development and commercialization of the products relating to cell and gene therapy products.

Licensor is a biotechnology company specializing in the development, manufacturing and provision of services in the cell and gene therapy industry. The Company is focused on the development of proprietary cell and gene therapies, including the autologous trans-differentiation technology, and therapeutic collaborations and licensing with other pre-clinical and clinical-stage biopharmaceutical companies and research and healthcare institutes. Another platform is comprised of a specialization in cell manufacturing and development.

Field of Use
This agreement pertains to the medical industry relating to cell therapy.

IPSCIO Record ID: 270502

License Grant
With the Joint Venture Agreement (JVA), the parties will collaborate in the clinical development and commercialization of the products.

In addition, under the JVA, Licensor shall, subject to fulfilment of the obligations grant the JV, an exclusive license to certain intellectual property of First Choice as may be required for the JV to develop and commercialize the Products globally.

Additionally, and for separate consideration, First Choice shall be granted a limited, non-exclusive license to certain rights relating to the Human Papilloma Virus.

License Property
The licensed property is the intellectual property needed for the development and commercialization of the products relating to cell and gene therapy products.

Licensor is a biotechnology company specializing in the development, manufacturing and provision of services in the cell and gene therapy industry. The Company is focused on the development of proprietary cell and gene therapies, including the autologous trans-differentiation technology, and therapeutic collaborations and licensing with other pre-clinical and clinical-stage biopharmaceutical companies and research and healthcare institutes. Another platform is comprised of a specialization in cell manufacturing and development.

Field of Use
This agreement pertains to the medical industry relating to cell therapy.

IPSCIO Record ID: 269376

License Grant
With the Joint Venture Agreement (JVA), the Licensor and the Greek Licensee will collaborate in the clinical development and commercialization of the Company’s products   Under the JVA, the Company shall, subject to fulfilment of Licensee’s terms to the JV, grant the JV Company an exclusive license to certain intellectual property of the Company as may be required for the JV Company to develop and commercialize the Products in the Territory.
License Property
The licensed property is the intellectual property needed for the development and commercialization of the products relating to cell and gene therapy products.

Licensor is a biotechnology company specializing in the development, manufacturing and provision of services in the cell and gene therapy industry. The Company is focused on the development of proprietary cell and gene therapies, including the autologous trans-differentiation technology, and therapeutic collaborations and licensing with other pre-clinical and clinical-stage biopharmaceutical companies and research and healthcare institutes. Another platform is comprised of a specialization in cell manufacturing and development.

Field of Use
This agreement pertains to the medical industry relating to cell therapy.

IPSCIO Record ID: 270500

License Grant
With the Joint Venture Agreement (JVA), the Greek parties will collaborate in the clinical development and commercialization the products worldwide. In addition, under the JVA, Licensor shall, subject to fulfilment of the Company’s terms to the JV, grant the JV Company an exclusive license to certain intellectual property of Licensor as may be required for the JV Company to develop and commercialize the Products globally.
License Property
The intellectual property are products needed for the development, manufacturing and provision of services in the cell and gene therapy industry.
Field of Use
This agreement pertains to the medical industry.

IPSCIO Record ID: 250259

License Grant
The Licensee and the Israeli Licensor agreed to collaborate in carrying out projects for the purpose of developing and commercializing the technology.

The Israeli Licensor granted an exclusive, worldwide license to make, develop and commercialize Licensor Entities’ rights in and to the Licensor Entities’ background intellectual property, the Project results, certain patents and the Joint IP, as well as products.

License Property
The technology is for a novel alginate scaffold technology for cell transplantation.
Field of Use
The field is treatment of autoimmune diseases, including, use of islets to treat diabetes.

IPSCIO Record ID: 26296

License Grant
The Licensor entered into an Agreement with the Sublicensee that granted them an exclusive subLicense relating to cell transfection technology for increased efficiency in loading genetic material into cells. The Licensor retains exclusive rights to the applications of the technologies involving cells for therapeutic applications, and received an upfront payment in addition to future royalties on net sales of Licensed products sold under the subLicense.
License Property
The Licensor owns the intellectual property rights to methods, compositions and devices that increase the frequency and efficiency of depositing particles into cells to modify their genetic code.
Field of Use
Licensee is a regenerative medicine company (a medical area that focuses on developing therapies that regenerate damaged or diseased tissues or organs) that incorporated in 1989 and focused on the clinical development of autologous cell products (cells collected from a patient and returned to that same patient) for the repair or regeneration of multiple human tissues, based on our proprietary Tissue Repair Cell (TRC) technology.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.